Search Browse Earnings

Bicara Therapeutics Inc.

Nasdaq:BCAX

Pharmaceutical Preparations·BOSTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Mazumdar Claire

CFO

Hyep Ivan

Revenue

—

Adj. EBITDA

-$39.9M

FY 2024

Net Income

-$52.0M

FY 2024

EPS (Diluted)

-$89.61

FY 2024

Stock Price

$20.05

+1.9%

2026-03-10

52W Range

$7.80 – $20.12

P/E Ratio

-0.2x

Market Cap

$1.1B

Cash

$230.4M

FY 2024

Total Debt

—

Net Cash

$230.4M

Enterprise Value

$867.9M

Debt / EBITDA

5.8x

FY 2024

EV / EBITDA

-21.8x

Employees

—